These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 25783861)

  • 41. T regulatory cell therapy: The price of specificity.
    Muckenhuber M; Wekerle T
    Am J Transplant; 2023 Dec; 23(12):1824-1825. PubMed ID: 37567450
    [No Abstract]   [Full Text] [Related]  

  • 42. News on the horizon in glioblastoma therapy.
    Herrlinger U
    ESMO Open; 2020 Feb; 5(1):. PubMed ID: 32054632
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Towards advanced cell therapies.
    Nat Biomed Eng; 2018 Jun; 2(6):339-340. PubMed ID: 31011200
    [No Abstract]   [Full Text] [Related]  

  • 44. Cancer: Precision T-cell therapy targets tumours.
    Melief CJM
    Nature; 2017 Jul; 547(7662):165-167. PubMed ID: 28678783
    [No Abstract]   [Full Text] [Related]  

  • 45. T-Cell Therapy to the Rescue.
    Pepple KL; Van Gelder RN
    Ophthalmol Retina; 2021 Sep; 5(9):835-837. PubMed ID: 34503757
    [No Abstract]   [Full Text] [Related]  

  • 46. Mechanisms regulating glioma invasion.
    Paw I; Carpenter RC; Watabe K; Debinski W; Lo HW
    Cancer Lett; 2015 Jun; 362(1):1-7. PubMed ID: 25796440
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Electrical device for patients with glioblastoma met with support, skepticism: some question the device's efficacy, others tout it as a new standard of care.
    Printz C
    Cancer; 2015 Apr; 121(7):969-70. PubMed ID: 25787834
    [No Abstract]   [Full Text] [Related]  

  • 48. Management of patients with recurrent glioblastoma using hypofractionated stereotactic radiotherapy.
    Dincoglan F; Beyzadeoglu M; Sager O; Demiral S; Gamsiz H; Uysal B; Ebruli C; Akin M; Oysul K; Sirin S; Dirican B
    Tumori; 2015; 101(2):179-84. PubMed ID: 25791534
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Retrospective analysis of bevacizumab in combination with fotemustine in chinese patients with recurrent glioblastoma multiforme.
    Liu Z; Zhang G; Zhu L; Wang J; Liu D; Lian L; Liu J; Lai T; Zhuang X
    Biomed Res Int; 2015; 2015():723612. PubMed ID: 25789324
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Correction: Podocalyxin promotes glioblastoma multiforme cell invasion and proliferation via β-catenin signaling.
    PLOS ONE Staff
    PLoS One; 2015; 10(3):e0119049. PubMed ID: 25785954
    [No Abstract]   [Full Text] [Related]  

  • 51. Molecular heterogeneity in glioblastoma: potential clinical implications.
    Parker NR; Khong P; Parkinson JF; Howell VM; Wheeler HR
    Front Oncol; 2015; 5():55. PubMed ID: 25785247
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The Antitumor Activity of Plant-Derived Non-Psychoactive Cannabinoids.
    McAllister SD; Soroceanu L; Desprez PY
    J Neuroimmune Pharmacol; 2015 Jun; 10(2):255-67. PubMed ID: 25916739
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The impact of bevacizumab on health-related quality of life in patients treated for recurrent glioblastoma: results of the randomised controlled phase 2 BELOB trial.
    Dirven L; van den Bent MJ; Bottomley A; van der Meer N; van der Holt B; Vos MJ; Walenkamp AM; Beerepoot LV; Hanse MC; Reijneveld JC; Otten A; de Vos FY; Smits M; Bromberg JE; Taal W; Taphoorn MJ;
    Eur J Cancer; 2015 Jul; 51(10):1321-30. PubMed ID: 25899986
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Delivery of local therapeutics to the brain: working toward advancing treatment for malignant gliomas.
    Chaichana KL; Pinheiro L; Brem H
    Ther Deliv; 2015 Mar; 6(3):353-69. PubMed ID: 25853310
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effective Eradication of Glioblastoma Stem Cells by Local Application of an AC133/CD133-Specific T-cell-Engaging Antibody and CD8 T Cells.
    Prasad S; Gaedicke S; Machein M; Mittler G; Braun F; Hettich M; Firat E; Klingner K; Schüler J; Wider D; Wäsch RM; Herold-Mende C; Elsässer-Beile U; Niedermann G
    Cancer Res; 2015 Jun; 75(11):2166-76. PubMed ID: 25840983
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Glioblastoma treatment patterns, survival, and healthcare resource use in real-world clinical practice in the USA.
    Girvan AC; Carter GC; Li L; Kaltenboeck A; Ivanova J; Koh M; Stevens J; Hayes-Larson E; Lahn MM
    Drugs Context; 2015; 4():. PubMed ID: 25834620
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Phase 1/2 trials of Temozolomide, Motexafin Gadolinium, and 60-Gy fractionated radiation for newly diagnosed supratentorial glioblastoma multiforme: final results of RTOG 0513.
    Brachman DG; Pugh SL; Ashby LS; Thomas TA; Dunbar EM; Narayan S; Robins HI; Bovi JA; Rockhill JK; Won M; Curran WP
    Int J Radiat Oncol Biol Phys; 2015 Apr; 91(5):961-7. PubMed ID: 25832688
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Glioblastoma-derived extracellular vesicles modify the phenotype of monocytic cells.
    de Vrij J; Maas SL; Kwappenberg KM; Schnoor R; Kleijn A; Dekker L; Luider TM; de Witte LD; Litjens M; van Strien ME; Hol EM; Kroonen J; Robe PA; Lamfers ML; Schilham MW; Broekman ML
    Int J Cancer; 2015 Oct; 137(7):1630-42. PubMed ID: 25802036
    [TBL] [Abstract][Full Text] [Related]  

  • 59. T-cell therapy targets glioblastoma.
    Cancer Discov; 2015 May; 5(5):458. PubMed ID: 25783861
    [No Abstract]   [Full Text] [Related]  

  • 60. Anti-EGFRvIII Chimeric Antigen Receptor-Modified T Cells for Adoptive Cell Therapy of Glioblastoma.
    Ren PP; Li M; Li TF; Han SY
    Curr Pharm Des; 2017; 23(14):2113-2116. PubMed ID: 28302023
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.